Consensus statement on preventive and symptomatic care of leukodystrophy patients.
Van Haren. Keith K; Bonkowsky. Joshua L JL; Bernard. Genevieve G; Murphy. Jennifer L JL; Pizzino. Amy A; Helman. Guy G; Suhr. Dean D; Waggoner. Jacque J; Hobson. Don D; Vanderver. Adeline A; Patterson. Marc C MC
Key Findings
- Leukodystrophies are inherited disorders that damage brain myelin.
- There are no cures, but many medical and psychosocial complications can be treated and prevented.
- The consensus outlines preventive care strategies and calls for more research on clinical needs.
Practical Outcomes
- For the biohacker community, the article offers little direct value; it mainly informs clinicians about managing a rare disease rather than providing actionable protocols for longevity, metabolic health, or performance.
Summary
This paper is a medical consensus on how to recognize and treat complications in people with leukodystrophy, a rare genetic brain disease, and it doesn’t discuss any peptide or self‑optimization strategies.
Abstract
Leukodystrophies are inherited disorders whose primary pathophysiology consists of abnormal deposition or progressive disruption of brain myelin. Leukodystrophy patients manifest many of the same symptoms and medical complications despite the wide spectrum of genetic origins. Although no definitive cures exist, all of these conditions are treatable. This report provides the first expert consensus on the recognition and treatment of medical and psychosocial complications associated with leukodystrophies. We include a discussion of serious and potentially preventable medical complications and propose several preventive care strategies. We also outline the need for future research to prioritize clinical needs and subsequently develop, validate, and optimize specific care strategies.
Study Information
pubmed
2014
2014-12-27T00:00:00.000Z
10.1016/j.ymgme.2014.12.433
37
45